机构:[1]Sun Yat Sen Univ, Canc Ctr, Guangzhou, Peoples R China[2]Guangzhou Med Univ, Affiliated Hosp 1, Guangzhou, Peoples R China[3]Meizhou Peoples Hosp, Huangtang Hosp, Meizhou, Peoples R China[4]Shantou Univ, Canc Hosp, Med Coll, Shantou, Peoples R China[5]Guangzhou Univ Chinese Med, Guangdong Prov Hosp Tradit Chinese Med, Affiliated Hosp 2, Guangzhou, Peoples R China广东省中医院[6]Guangzhou Univ Chinese Med, Guangdong Hong Kong Macau Joint Lab Chinese Med &, Guangzhou, Peoples R China[7]Guangzhou Red Cross Hosp, Guangzhou, Peoples R China[8]Jiangsu Hengrui Pharmaceut Co Ltd, Shanghai, Peoples R China
第一作者机构:[1]Sun Yat Sen Univ, Canc Ctr, Guangzhou, Peoples R China
推荐引用方式(GB/T 7714):
Hou X.,Zhou C.,Wu G.,et al.First-Line Camrelizumab Plus Chemotherapy for Advanced Non-squamous NSCLC with Brain Metastases: Updated Data from CAP-BRAIN[J].JOURNAL OF THORACIC ONCOLOGY.2023,18(11):S318-S318.
APA:
Hou, X.,Zhou, C.,Wu, G.,Lin, W.,Xie, Z....&Chen, L..(2023).First-Line Camrelizumab Plus Chemotherapy for Advanced Non-squamous NSCLC with Brain Metastases: Updated Data from CAP-BRAIN.JOURNAL OF THORACIC ONCOLOGY,18,(11)
MLA:
Hou, X.,et al."First-Line Camrelizumab Plus Chemotherapy for Advanced Non-squamous NSCLC with Brain Metastases: Updated Data from CAP-BRAIN".JOURNAL OF THORACIC ONCOLOGY 18..11(2023):S318-S318